Guanhao Biotech Co Ltd (SHE:300238) — Market Cap & Net Worth
Market Cap & Net Worth: Guanhao Biotech Co Ltd (300238)
Guanhao Biotech Co Ltd (SHE:300238) has a market capitalization of $429.13 Million (CN¥2.93 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13194 globally and #3944 in its home market, demonstrating a 1.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guanhao Biotech Co Ltd's stock price CN¥11.06 by its total outstanding shares 265155701 (265.16 Million). Review how much debt does Guanhao Biotech Co Ltd carry to assess the company's total debt and financial obligations.
Guanhao Biotech Co Ltd Market Cap History: 2015 to 2026
Guanhao Biotech Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.19 Billion to $429.13 Million (-11.23% CAGR).
Guanhao Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guanhao Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.40x
Guanhao Biotech Co Ltd's market cap is 1.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.07x
Guanhao Biotech Co Ltd's market cap is 22.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.29 Billion | $312.79 Million | $56.96 Million | 4.11x | 22.58x |
| 2017 | $922.67 Million | $460.60 Million | $45.52 Million | 2.00x | 20.27x |
| 2018 | $370.16 Million | $458.46 Million | $45.75 Million | 0.81x | 8.09x |
| 2019 | $741.48 Million | $437.89 Million | -$465.33 Million | 1.69x | N/A |
| 2020 | $975.45 Million | $436.96 Million | $46.59 Million | 2.23x | 20.93x |
| 2021 | $718.98 Million | $488.98 Million | $73.69 Million | 1.47x | 9.76x |
| 2022 | $398.87 Million | $377.29 Million | -$307.82 Million | 1.06x | N/A |
| 2023 | $526.14 Million | $404.18 Million | $31.01 Million | 1.30x | 16.97x |
| 2024 | $467.16 Million | $377.48 Million | $27.42 Million | 1.24x | 17.04x |
| 2025 | $537.39 Million | $383.42 Million | $24.35 Million | 1.40x | 22.07x |
Competitor Companies of 300238 by Market Capitalization
Companies near Guanhao Biotech Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Guanhao Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Guanhao Biotech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guanhao Biotech Co Ltd's market cap moved from $2.19 Billion to $ 429.13 Million, with a yearly change of -11.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥429.13 Million | -20.14% |
| 2025 | CN¥537.39 Million | +15.03% |
| 2024 | CN¥467.16 Million | -11.21% |
| 2023 | CN¥526.14 Million | +31.91% |
| 2022 | CN¥398.87 Million | -44.52% |
| 2021 | CN¥718.98 Million | -26.29% |
| 2020 | CN¥975.45 Million | +31.55% |
| 2019 | CN¥741.48 Million | +100.31% |
| 2018 | CN¥370.16 Million | -59.88% |
| 2017 | CN¥922.67 Million | -28.26% |
| 2016 | CN¥1.29 Billion | -41.15% |
| 2015 | CN¥2.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Guanhao Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $429.13 Million USD |
| MoneyControl | $429.13 Million USD |
| MarketWatch | $429.13 Million USD |
| marketcap.company | $429.13 Million USD |
| Reuters | $429.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; T… Read more